IUGNF - Imugene thrilled as VAXINIA granted FDA Fast Track designation

(NewsDirect)

Imugene Ltd(ASX:IMU, OTC:IUGNF) CEO Leslie Chong and chief medical officer DrPaul Woodard speak with Proactive following the news it’s beengranted 'Fast Track' designation from the US Food and DrugAdministration (FDA) for its MAST (metastatic advanced solid tumours)clinical program — evaluating the safety and efficacy of novelcancer-killing virus CF33-hNIS (VAXINIA). The FDA’s Fast Trackdesignation is awarded to help important new therapies reach patientsearlier. It is designed to facilitate the development and expedite thereview of drug candidates to treat serious conditions and fill anunmet medical need.

“The Fast Track process of drug development is designed tofacilitate the development, and the review of drugs to treat seriousconditions and fill an unmet medical need, with fast track statusoften leading to earlier drug approval and access by patients,”Chong said.

ContactDetails

Proactive Investors

JonathanJackson

+61 413 713 744

Jonathan@proactiveinvestors.com

Copyright (c) 2023 TheNewswire - All rights reserved.